Type 2 diabetes (T2D) is characterized by insulin resistance i.e., inability of tissues to respond to insulin, and a progressive pancreatic beta cell dysfunction in response to glucose levels. The disease is thought to be caused by environmental and inherited factors in about equal proportions. Many environmental risk factors are known and they include obesity, sedentary lifestyle, stress, nutritional factors and toxins[@b1][@b2]. Family history is an important risk factor which has been shown in twins and singleton siblings[@b1][@b3]. The prevalence of T2D varies in populations and the rate has been increasing in many global populations, including Sweden[@b4][@b5].

There are solid epidemiological data indicating that families of T2D patients show an excess of type 1 diabetes (T1D) which is an autoimmune disease (AId)[@b6][@b7][@b8]. Additionally, latent autoimmune diabetes of the adult (LADA) or of the young (LADY) show clustering with both T2D and T1D[@b9][@b10]. Recent data confirm some shared genetic predispositions for both types of diabetes and the classification has become difficult particularly in obese adolescents[@b11]. Furthermore, T2D has been found to express autoimmune characteristics, including the presence of autoantibodies against pancreatic beta cells and self-reactive T-cells. Glucose-lowering effects of some immune modulatory therapies in T2D patients have been related to the role of inflammasome pathways in T2D, shared by AIds with an inflammatory component[@b11]. Accordingly, associations have been observed between psoriasis and T2D, and rheumatoid arthritis and T2D[@b12][@b13]. A population-level source for study of disease co-morbidity is available in Sweden through the national Hospital Discharge Register, the Outpatient Register and the regional primary health care registers[@b14][@b15][@b16][@b17][@b18]. In the present article we study individual risks for subsequent T2D among patients diagnosed with any of 32 AIds. With a total AId patient population of 757,368 and 15,103 subsequent T2D diagnoses this is the largest study published on these diseases with the advantage that all the results emanate from a single population of medically confirmed cases in a country of high medical standard and reasonably uniform diagnostics.

Materials and Methods
=====================

The research database used for this study is a subset of the national datasets compiled at Center for Primary Health Care Research, Lund University, Malmo. The data were analyzed anonymously because we used the registration data from several Swedish national registers. AId and T2D patients were identified from three health care databases: national Hospital Discharge Register including all hospital discharges with dates of hospitalization and diagnoses between 1964 and 2010, national Outpatient Registry from 2001 to 2010 and Primary Health Care Registry in Stockholm (2001--2007) and Region Skane (1987--2010). These databases include all patient visits for the described periods. When a person was present in multiple registers, the first diagnosis was considered. Various versions of the International Classification of Diseases (ICD) codes were used for case identification. For T2D, until 1996 ICD code identified diabetes without specifications and therefore age 40 year at first hospitalization was used to define T2D; this cutoff is also used in the Swedish Diabetes Register (<https://www.ndr.nu>). Those who had diabetes diagnosis before age 40 years were excluded. The ICD-10 code E11 'non-insulin dependent diabetes' was used from 1997 onwards. T1D was not included among AIds because ICD-10 code 'insulin dependent diabetes' also includes T2D patients treated with insulin. Using code E11 for T2D would exclude T2D patients treated with insulin.

Person-years were calculated from the date of the first medical diagnosis for AId until diagnosis of T2D, death, emigration, or closing date on December 31, 2010, whichever came first. Standardized incidence ratios (SIRs) were calculated as the ratio of observed (O) to expected number of cases[@b19]. We used the indirect standardization method ([Equation 1](#eq1){ref-type="disp-formula"}):

Where *O* = ∑*o*~*j*~denotes the total number of observed cases in the study group; *E*^*\**^ (expected number of cases) is calculated by applying stratum-specific standard incidence rates (*λ*^*\**^~*j*~) obtained from the reference group (all individuals without AId) to the stratum-specific person-years at risk (*n*~*j*~) of experience in the study group; *O*~*j*~ represents the observed number of cases that cohort subjects contribute to the *j*th stratum; and *J* represents the strata defined by the cross-classification of the following adjustment variables: age (5-year groups), sex, time period (5-year groups), socioeconomic status (6 groups), and geographic region of residence (3 groups). The 95% confidence intervals (CIs) were calculated and rounded to two decimal places for SIR, assuming a Poisson distribution. In this study, the result is statistically significant if the 95% CI does not include 1.00.

In reverse analysis the risk of AId was analyzed after T2D diagnosed at age below 60 years.

The methods in the present study were carried out in the accordance with the approved guidelines of the Regional Ethical Review Board of Lund University.

Ethics Statement
----------------

This study was approved by the Regional Ethical Review Board of Lund University in Sweden.

The data used in the present study were obtained from several Swedish Registers and they were analyzed anonymously.

Results
=======

The total number of unique patients diagnosed with any of the 32 AIds was 757,368, accumulating close to 7 million person-years at risk for T2D ([Table 1](#t1){ref-type="table"}). The most common individual diseases were psoriasis, rheumatoid arthritis, Graves/hyperthyroidism and Hashimoto/hypothyroidism. These diseases were more common in women compared to men, similar to all AId cases. The largest female excess, 7-fold, was noted for Sjogren syndrome. The median ages for the first registered medical contacts for AId ranged from 15 years for celiac disease to 75 years for pernicious anemia.

The largest source of patient identification was the Outpatient Register which accounted for 437,000 notifications of 972,000 for all AIds (inpatients 382,000 and primary care 153,000) (data not shown). Some patients were registered in multiple sources but the number of unique AId patients was 757,368. For T2D the numbers were 132,000 of a total of 231,000 (inpatients 53,000 and primary care 46,000); the number of unique T2D patients was 168,992.

The overall risk of T2D after any AId was 1.66 (95% CI 1.63--1.68), essentially similar for men and women ([Table 2](#t2){ref-type="table"}). Only SIRs with statistical significance, i.e., their CIs did not overlap with 1.00, were presented in the following texts. For both sexes T2D risks were increased for 27 AIds while 5 AIs showed no increase but these had generally small numbers of cases. The largest SIRs were noted for chorea minor (8.00, 95% CI 3.81--14.77), lupoid hepatitis (5.75, 95% CI 4.46--7.29), and Addison disease (2.63, 95% CI 2.16--3.18). Clear risks of T2D were also found for common AIds (based on [Table 1](#t1){ref-type="table"}), such as psoriasis (2.03, 95% CI 1.96--2.10), rheumatoid arthritis (1.50, 95% CI 1.44--1.57), Graves/hyperthyroidism (1.47, 95% CI 1.41--1.54), Hashimoto/hypothyroidism (2.01, 95% CI 1.92--2.10), and ulcerative colitis (1.73, 95% CI 1.64--1.82). A significant sex-difference for T2D was observed only for chronic rheumatic heart disease (1.44, 95% CI 1.26--1.64 for men and 1.94, 95% CI 1.70--2.20 for women) and psoriasis (1.88, 95% CI 1.78--1.97 for men and 2.22, 95% CI 2.11--2.34 for women). For T2D after polymyalgia rheumatica the difference was of borderline significance (1.68, 95% CI 1.56--1.81 for men and 1.92, 95% CI 1.81--2.03 for women). For Sjogren syndrome, with an extreme female excess in case numbers, the SIRs showed no large sex differences: 1.67 (95% CI 1.29--2.12) for men and 1.50 (95% CI 1.33--1.68) for women.

Early age at T2D diagnosis was associated with an increased risk ([Table 3](#t3){ref-type="table"}). For all AIds the SIR was 2.43 (95% CI 2.30--2.56) when T2D was diagnosed before age 50; it was 1.78 (95% CI 1.74--1.83) when diagnosis was between 50 and 69 years and it was 1.48 (95% CI 1.44--1.51) when diagnosis was at 70+ years. At early age of onset very high SIRs were noted for lupoid hepatitis (16.85, 95% CI 8.93--28.90) and polymyositis/dermatomyositis (7.34, 95% CI 4.00--12.34).

The analysis was also carried out in reverse order. Because it was necessary to allow some follow-up time only T2D cases diagnosed before age 60 years (N = 49358) were considered ([Table 4](#t4){ref-type="table"}). As expected, the overall risk was highest for concurrent diagnosis (2.93, 95% CI 2.77--3.10, follow-up ≤1 year) but it was increased also for period 2--5 years (1.62, 95% CI 1.52--1.73) and for period 6+ years (1.91, 95% CI 1.77--2.06). In the latter period, SIRs were increased for 12 AIds, most for lupoid hepatitis (6.10, 95% CI 2.61--12.08), Wegener granumatolosis (5.36, 95% CI 2.84--9.19), primary biliary cirrhosis (4.97, 95% CI 2.56--8.71), and sarcoidosis (3.06, 95% CI 2.10--4.30).

Discussion
==========

To our knowledge this is a first nationwide attempt to assess risks for T2D after many types of AIds using unified data (and in reverse order). We used three population-level sources available in Sweden to identify patients: national Hospital Discharge Register, national Outpatient Register and a regional primary health care register. The total T2D population covered was 231,000 which is less than the year 2004 Swedish estimate at 350,000 T2D patients[@b20]. For year 2012 the National Swedish Diabetes Register, with some 90% coverage, reported 346,000 patients of any type of diabetes; of these were 34,000 T1D patients from the Hospital Discharge Register (www.ndr.nu). The number of T2D patients was not given but subtracting T1D patients the estimate for T2D would be around 300,000. We know that the present coverage of primary care is not complete and a proportion of persons only diagnosed in primary care would be missing. However, for the present approach it is more important that T2D diagnoses are correct rather than the coverage is complete, yet with the caveat that severe cases are most likely to be hospitalized. Because of the diagnostic codes and age limits used we assume that 'contamination' by T1D patients is small.

A similar discussion on diagnostic accuracy and coverage is of course relevant for AIds. Ad hoc studies from Sweden have shown 85 to 95% diagnostic accuracies for Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease, and Wegener granulomatosis[@b14][@b21][@b22][@b23]. The overall diagnostic accuracy in the Swedish Hospital Discharge Register has been referred to as being 88--90% on main diagnoses[@b17][@b23]. With poor diagnostic accuracy any effects would be expected to regress towards null, which appeared not to be the case with the present results. Another related issue is the possibility for diagnostic and surveillance bias for antedated T2D diagnosis during treatment for AId. While some degree of this kind of bias probably usually exists for chronic diseases it is likely not to be an important contributor, for example, in view of the results in [Table 3](#t3){ref-type="table"}. If bias were present it should not depend on the diagnostic age of T2D. In [Table 4](#t4){ref-type="table"} we see clear evidence on surveillance bias in the form of high risks of AIds in the same year when T2D was diagnosed. Another cause for co-morbidity may relate to socio-medical reasons and a tendency for patients to seek multiple medical contacts for various reasons, such as a labile disease control, referred to as 'brittle' diseases[@b24][@b25].

The overall findings showed that T2D was increased in patients diagnosed with any of 27 AIds, and chorea minor (SIR 8.00, 95% CI 3.81--14.77) and lupoid hepatitis (5.75, 95% CI 4.46--7.29) showed the highest risks. We found no related data on lupoid (autoimmune) hepatitis but chorea minor and hemichorea have been described as a common presenting feature of metabolic disorders, including nonketotic hyperglycemia in T2D patients[@b26]. T2D was also increased in patients with common AIds, such as psoriasis (2.03, 95% CI 1.96--2.10), rheumatoid arthritis (1.50, 95% CI 1.44--1.57), Graves/hyperthyroidism (1.47, 95% CI 1.41--1.54), Hashimoto/hypothyroidism (2.01, 95% CI 1.92--2.10), and ulcerative colitis (1.73, 95% CI 1.64--1.82). Hazards ratios for T2D after psoriasis and rheumatoid arthritis, based on Canadian healthcare records, were increased to 1.4 and 1.5, respectively[@b12]. T2D risk was also increased after psoriasis but not after rheumatoid arthritis after adjustments for body-mass index (BMI), smoking and alcohol consumption in a UK study[@b13]. An increased odds ratio (2.81), adjusted for gender, age and weight, was reported for newly identified hypothyroidism in patients with T2D[@b27]. There are mechanistic links through the inflammasome pathway and many shared genes between T2D and inflammatory bowel disease but epidemiological data have been lacking[@b28]. In support of such sharing, several AIds were increased when these were recorded after T2D ([Table 4](#t4){ref-type="table"}). The highest risk (6.10, 95% CI 2.61--12.08) with follow-up of 6+ years was observed for lupoid hepatitis which strong association (5.75, 95% CI 4.46--7.29) was also noted when T2D followed lupoid hepatitis ([Table 2](#t2){ref-type="table"}).

The case numbers of recorded AId patients were almost twice higher for women than for men overall but for Sjogren syndrome these were 7 times higher. Yet, the overall risk of T2D was essentially similar for men and women which implied that diabetes risk was proportional to the sex-specific background incidence of AId. The only significantly different SIRs for T2D were detected for chronic rheumatic heart disease and psoriasis patients and, at borderline, for polymyalgia rheumatica patients.

Many environmental and host factors predispose to T2D and one of the weaknesses of the present study was that we were unable to control for factors such as obesity, physical inactivity, smoking, and alcohol consumption, some of which may be risk factors for certain AIds[@b1][@b2]. For example, smoking is a known risk factor for psoriasis and Graves/hyperthyroiditis and it is prudent to assume that smoking may contribute to the observed associations of these diseases with T2D[@b29]. Some AIds may involve limitations in movement and the resulting physical inactivity and weight gain may promote T2D. There are also data associating obesity and AIds[@b30]. Also medication for AId would be a hypothetical trigger of T2D but it would not explain the reverse associations. The previously cited study on T2D risks in psoriasis and rheumatoid arthritis patients found that adjustment for BMI, smoking, and alcohol consumption reduced the risk[@b13]. However, the present clearly increased risks for T2D in most types of AId patients do not support an overall role for life-style related confounding factors. Instead, we assume that there are mechanistic links shared by T2D, AId and some life-style factors such as obesity and physical inactivity. If AId and T2D would share mechanistic pathways one could assume that there might be presentation of multiple AIds in the same individual or that there would be familial clustering of several AIds. There is ample evidence on familial clustering[@b18][@b31][@b32][@b33][@b34][@b35][@b36]. Although mechanistic schemes are speculative and beyond this paper, we conclude by hypothesising that chronic inflammation-driven activation may be a shared initiation mechanism for T2D and many AIds[@b10].
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###### Clinical characteristics of all autoimmune diseases.

  **Autoimmune disease**             **Gender (No.)**   **All (No.)**   **Median age at diagnosis**       
  --------------------------------- ------------------ --------------- ----------------------------- ---- -----------
  Addison disease                         1,646             2,392                  4,038              56    37,830
  Amyotrophic lateral sclerosis           5,451             4,241                  9,695              67    40,773
  Ankylosing spondylitis                  11,448            6,191                 17,639              44    173,893
  Autoimmune hemolytic anemia              576               831                   1,407              68    13,878
  Behcet disease                          2,669             1,757                  4,426              44    76,817
  Celiac disease                          15,385           26,012                 41,397              15    404,585
  Chorea minor                              43               78                     121               53     1,161
  Chronic rheumatic heart disease         11,701           13,413                 25,114              65    249,501
  Crohn disease                           21,146           22,787                 43,933              41    431,430
  Discoid lupus erythematosus             1,034             3,131                  4,165              55    31,894
  Graves/hyperthyroidism                  14,875           70,764                 85,639              55    955,016
  Hashimoto/hypothyroidism                13,503           70,085                 83,588              55    570,633
  Immune thrombocytopenic purpura         3,807             4,259                  8,066              43    68,014
  Localized scleroderma                    874              2,683                  3,557              54    31,250
  Lupoid hepatitis                         524              1,300                  1,824              54     8,055
  Multiple sclerosis                      8,726            17,345                 26,071              48    227,157
  Myasthenia gravis                       1,849             2,366                  4,215              62    40,877
  Pernicious anemia                       5,653             6,994                 12,647              75    129,371
  Polyarteritis nodosa                    1,031             1,101                  2,132              63    19,340
  Polymyalgia rheumatica                  17,898           34,072                 51,970              73    457,669
  Polymyositis/dermatomyositis            1,514             2,229                  3,743              60    34,458
  Primary biliary cirrhosis                684              2,942                  3,626              64    20,564
  Psoriasis                               61,982           69,223                 131,205             52    886,507
  Reiter disease                           597               162                    759               42     7,930
  Rheumatic fever                         3,139             1,513                  4,652              45    93,135
  Rheumatoid arthritis                    37,575           87,520                 125,095             63   1,044,906
  Sarcoidosis                             11,128           10,571                 21,699              48    257,076
  Sjögren syndrome                        1,765            12,804                 14,569              60    103,979
  Systemic lupus erythematosus            2,238             9,968                 12,206              53    103,559
  Systemic sclerosis                      3,643             5,061                  8,704              58    113,085
  Ulcerative colitis                      35,487           31,815                 67,302              43    658,554
  Wegener granulomatosis                  5,805            11,346                 17,151              72    192,329
  All                                    279,879           477,489                757,368             56   6,995,377

Abbreviations: Pyrs, person-years.

###### SIRs for type 2 diabetes mellitus after a specified autoimmune disease by gender.

  **Autoimmune disease**             **All**  **Male**    **Female**                                                     
  --------------------------------- --------- ---------- ------------- ------ ---------- ------------- ------ ---------- -------------
  Addison disease                      108    **2.63**    2.16--3.18     38   **2.04**    1.44--2.80     70   **3.14**    2.44--3.96
  Amyotrophic lateral sclerosis        43     0.84        0.61--1.14     29   0.83        0.56--1.20     14   0.87        0.47--1.46
  Ankylosing spondylitis               314    **1.32**    1.17--1.47    223   **1.23**    1.08--1.40     91   **1.58**    1.27--1.94
  Autoimmune hemolytic anemia          21     **1.77**    1.09--2.71     12   **2.04**    1.05--3.58     9    1.51        0.68--2.87
  Behcet disease                       81     1.24        0.98--1.54     58   1.18        0.89--1.52     23   1.41        0.90--2.13
  Celiac disease                       251    1.10        0.96--1.24    134   **1.22**    1.02--1.44    117   0.98        0.81--1.18
  Chorea minor                         10     **8.00**    3.81--14.77    4    **8.34**    2.17--21.56    6    **7.79**    2.80--17.07
  Chronic rheumatic heart disease      476    **1.66**    1.51--1.82    229   **1.44**    1.26--1.64    247   **1.94**    1.70--2.20
  Crohn disease                        713    **1.54**    1.43--1.66    407   **1.51**    1.37--1.67    306   **1.58**    1.41--1.77
  Discoid lupus erythematosus          60     1.09        0.83--1.41     22   1.15        0.72--1.74     38   1.06        0.75--1.46
  Graves/hyperthyroidism              1772    **1.47**    1.41--1.54    410   **1.49**    1.35--1.64    1362  **1.47**    1.39--1.55
  Hashimoto/hypothyroidism            2013    **2.01**    1.92--2.10    430   **2.09**    1.89--2.29    1583  **1.99**    1.89--2.09
  Immune thrombocytopenic purpura      182    **2.46**    2.12--2.85     97   **2.42**    1.96--2.96     85   **2.51**    2.00--3.10
  Localized scleroderma                75     **1.72**    1.35--2.15     22   **1.90**    1.19--2.88     53   **1.65**    1.24--2.16
  Lupoid hepatitis                     68     **5.75**    4.46--7.29     23   **5.41**    3.42--8.13     45   **5.94**    4.33--7.95
  Multiple sclerosis                   303    **1.22**    1.09--1.37    120   1.12        0.92--1.33    183   **1.30**    1.12--1.51
  Myasthenia gravis                    92     **1.68**    1.36--2.06     53   **1.79**    1.34--2.34     39   **1.56**    1.11--2.13
  Pernicious anemia                    140    **1.21**    1.01--1.42     86   **1.39**    1.11--1.72     54   0.99        0.75--1.30
  Polyarteritis nodosa                 52     **2.01**    1.50--2.64     30   **2.21**    1.49--3.16     22   **1.79**    1.12--2.71
  Polymyalgia rheumatica              1900    **1.82**    1.74--1.91    724   **1.68**    1.56--1.81    1176  **1.92**    1.81--2.03
  Polymyositis/dermatomyositis         94     **2.10**    1.70--2.58     51   **2.32**    1.73--3.05     43   **1.90**    1.37--2.56
  Primary biliary cirrhosis            96     **2.18**    1.77--2.66     26   **2.63**    1.72--3.86     70   **2.05**    1.60--2.59
  Psoriasis                           3028    **2.03**    1.96--2.10    1579  **1.88**    1.78--1.97    1449  **2.22**    2.11--2.34
  Reiter disease                       14     1.20        0.65--2.02     12   1.17        0.60--2.06     2    1.40        0.13--5.14
  Rheumatic fever                      118    **1.32**    1.09--1.58     84   1.20        0.96--1.49     34   **1.77**    1.22--2.47
  Rheumatoid arthritis                2070    **1.50**    1.44--1.57    788   **1.52**    1.42--1.63    1282  **1.49**    1.41--1.57
  Sarcoidosis                          646    **2.11**    1.95--2.28    346   **2.02**    1.81--2.24    300   **2.24**    1.99--2.51
  Sjögren syndrome                     353    **1.52**    1.37--1.69     65   **1.67**    1.29--2.12    288   **1.50**    1.33--1.68
  Systemic lupus erythematosus         201    **1.83**    1.59--2.10     44   **1.50**    1.09--2.02    157   **1.95**    1.66--2.28
  Systemic sclerosis                   129    **1.34**    1.12--1.60     71   **1.44**    1.13--1.82     58   1.24        0.94--1.61
  Ulcerative colitis                  1359    **1.73**    1.64--1.82    875   **1.77**    1.66--1.89    484   **1.65**    1.51--1.81
  Wegener granulomatosis               215    **1.45**    1.26--1.66     80   **1.44**    1.14--1.79    135   **1.46**    1.22--1.73
  All                                 15103   **1.66**    1.63--1.68    6519  **1.62**    1.58--1.66    8584  **1.68**    1.65--1.72

Bold type indicates that the 95% CI does not include 1.00.

Abbreviations: O, observed; SIR, standardized incidence ratio; CI, confidence interval.

###### SIRs for T2D after a specified autoimmune disease by age at T2D diagnosis.

  **Autoimmune disease**             **\<50**  **50--69**      **≥70**                                                       
  --------------------------------- ---------- ------------ ------------- ------ ----------- ------------- ------ ---------- -------------
  Addison disease                       7      2.46          0.97--5.10     51   **3.21**     2.39--4.23     50   **2.24**    1.67--2.96
  Amyotrophic lateral sclerosis         7      **4.67**      1.85--9.67     10   0.53         0.25--0.98     26   0.85        0.55--1.24
  Ankylosing spondylitis                48     **2.09**      1.54--2.77    186   **1.28**     1.10--1.48     80   1.14        0.90--1.42
  Autoimmune hemolytic anemia           1      1.52          0.00--8.73     10   **2.67**     1.27--4.93     10   1.34        0.64--2.48
  Behcet disease                        8      1.45          0.62--2.88     47   1.32         0.97--1.76     26   1.06        0.69--1.56
  Celiac disease                        50     **1.81**      1.34--2.38    129   **1.22**     1.02--1.45     72   **0.75**    0.59--0.95
  Chorea minor                          1      7.01          0.00--40.18    5    **10.19**    3.22--23.98    4    **6.48**    1.69--16.77
  Chronic rheumatic heart disease       14     **2.20**      1.20--3.70    159   **2.08**     1.77--2.43    303   **1.49**    1.32--1.66
  Crohn disease                        100     **1.94**      1.58--2.36    392   **1.63**     1.47--1.80    221   **1.30**    1.14--1.49
  Discoid lupus erythematosus           4      1.28          0.33--3.31     33   1.25         0.86--1.76     23   0.90        0.57--1.36
  Graves/hyperthyroidism               132     **1.89**      1.58--2.24    714   **1.55**     1.43--1.66    926   **1.38**    1.29--1.47
  Hashimoto/hypothyroidism             230     **3.89**      3.40--4.43    842   **2.19**     2.05--2.35    941   **1.68**    1.58--1.79
  Immune thrombocytopenic purpura       12     **2.03**      1.04--3.55     77   **3.04**     2.40--3.80     93   **2.18**    1.76--2.67
  Localized scleroderma                 6      2.29          0.83--5.03     37   **2.34**     1.65--3.23     32   1.26        0.86--1.78
  Lupoid hepatitis                      13     **16.85**     8.93--28.90    37   **6.55**     4.61--9.03     18   **3.33**    1.97--5.27
  Multiple sclerosis                    47     **2.43**      1.79--3.23    152   1.08         0.91--1.26    104   1.19        0.97--1.44
  Myasthenia gravis                     9      **3.69**      1.67--7.03     32   **1.70**     1.16--2.40     51   **1.53**    1.14--2.01
  Pernicious anemia                     3      1.97          0.37--5.83     32   **1.66**     1.13--2.35    105   1.10        0.90--1.33
  Polyarteritis nodosa                  2      2.16          0.20--7.94     23   **2.65**     1.68--3.98     27   **1.66**    1.09--2.42
  Polymyalgia rheumatica                19     **2.52**      1.52--3.95    413   **1.90**     1.72--2.09    1468  **1.79**    1.70--1.89
  Polymyositis/dermatomyositis          14     **7.34**      4.00--12.34    39   **2.21**     1.57--3.02     41   **1.63**    1.17--2.22
  Primary biliary cirrhosis             3      4.38          0.83--12.96    44   **2.40**     1.74--3.22     49   **1.96**    1.45--2.59
  Psoriasis                            343     **2.93**      2.63--3.26    1638  **2.12**     2.02--2.22    1047  **1.74**    1.63--1.84
  Reiter disease                        3      1.82          0.34--5.38     9    1.22         0.55--2.33     2    0.75        0.07--2.77
  Rheumatic fever                       7      1.17          0.46--2.43     68   **1.49**     1.16--1.89     43   1.14        0.83--1.54
  Rheumatoid arthritis                  88     **2.43**      1.95--2.99    761   **1.69**     1.57--1.82    1221  **1.37**    1.29--1.45
  Sarcoidosis                           77     **2.91**      2.30--3.64    331   **2.19**     1.96--2.44    238   **1.86**    1.63--2.12
  Sjögren syndrome                      22     **2.88**      1.80--4.36    175   **1.77**     1.51--2.05    156   **1.25**    1.06--1.46
  Systemic lupus erythematosus          24     **3.44**      2.20--5.12     96   **1.96**     1.59--2.40     81   **1.50**    1.19--1.87
  Systemic sclerosis                    15     **2.26**      1.26--3.74     50   1.24         0.92--1.64     64   **1.31**    1.01--1.67
  Ulcerative colitis                   157     **1.94**      1.65--2.27    735   **1.90**     1.76--2.04    467   **1.46**    1.33--1.60
  Wegener granulomatosis                1      0.81          0.00--4.62     48   **2.52**     1.86--3.34    166   **1.30**    1.11--1.51
  All                                  1309    **2.43**      2.30--2.56    6524  **1.78**     1.74--1.83    7270  **1.48**    1.44--1.51

Bold type indicates that the 95% CI does not include 1.00.

Abbreviations: O, observed; SIR, standardized incidence ratio; CI, confidence interval.

###### SIRs for autoimmune diseases after type 2 diabetes mellitus by follow-up time (age at T2DM diagnosis \<60 years).
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Bold type indicates that the 95% CI does not include 1.00. Abbreviations: O, observed; SIR, standardized incidence ratio; CI, confidence interval.
